Active Biotech ABOSTO:ACTI +2.31%28 PB Ratio is 3.21 as of Jun. 25, 2026, which is 20% below its 10-year median of 4.02. GuruFocus rates OSTO:ACTI with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 1,233 Biotechnology companies, Active Biotech AB ranks worse than 54.66% on this metric.
Active Biotech AB stock PB Ratio (=3.14) is close to 2-year high of 3.21.
The historical rank and industry rank for Active Biotech AB's PB Ratio or its related term are showing as below:
OSTO:ACTI'
s PB Ratio Range Over the Past 10 Years
Min: 0.43 Med: 4.02 Max: 13.49
Current: 3.21
During the past 13 years, Active Biotech AB's highest PB Ratio was 13.49. The lowest was 0.43. And the median was 4.02.
OSTO:ACTI's PB Ratio is ranked worse than 54.66% of 1233
companies
in the Biotechnology industry
Industry Median: 2.83
vs OSTO:ACTI: 3.21
During the past 12 months, Active Biotech AB's average Book Value Per Share Growth Rate was 27.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -20.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -18.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -26.10% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Active Biotech AB was 36.60% per year. The lowest was -46.80% per year. And the median was -24.10% per year.
Back to Basics: PB Ratio
Active Biotech AB (OSTO:ACTI) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Active Biotech AB PB Ratio Related Terms
Active Biotech AB PB Ratio Historical Data
* Premium members only.
The historical data trend for Active Biotech AB's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:ACTI vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, Active Biotech AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Active Biotech AB PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Active Biotech AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Active Biotech AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Active Biotech AB (OSTO:ACTI) has a PB Ratio of 3.21 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Active Biotech AB and its competitors. This is 20% below median its historical median of 4.02. Over the past decade, Active Biotech AB's PB Ratio has ranged from 0.43 to 13.49. According to the industry distribution chart, Active Biotech AB ranks #674 out of 1233 companies in the Biotechnology industry, placing it in the top 54.7%.
Is Active Biotech AB's PB Ratio too high?
Active Biotech AB's current PB Ratio of 3.21 is 20% below median its 10-year median of 4.02. Over the past 10 years, this metric has ranged from a low of 0.43 to a high of 13.49. The Biotechnology industry median PB Ratio is 2.83. Active Biotech AB's value of 3.21 is 13.4% above this industry median. Based on the distribution chart, Active Biotech AB ranks #674 out of 1233 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Active Biotech AB has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Active Biotech AB's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Active Biotech AB ranks #674 out of 1233 companies for PB Ratio. This places Active Biotech AB in the lower half of its industry. The industry median PB Ratio is 2.83. Active Biotech AB's value of 3.21 is 13.4% above this benchmark. Historically, Active Biotech AB's own PB Ratio has ranged from 0.43 to 13.49 over the past decade. While the company's 10-year median is 4.02 vs. the industry median of 2.83, Active Biotech AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.83, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Active Biotech AB's current PB Ratio of 3.21 is 13.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Active Biotech AB and its competitors. For the Biotechnology industry, the median PB Ratio is 2.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Active Biotech AB's current PB Ratio is 3.21, which is 20% below median its own 10-year median of 4.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Active Biotech AB stock overvalued right now?
Active Biotech AB (OSTO:ACTI) has a current PB Ratio of 3.21. The current PB Ratio is 3.21, which is 20% below median its 10-year median of 4.02 and 13.4% above the Biotechnology industry median of 2.83. Active Biotech AB's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Active Biotech AB (OSTO:ACTI), the current PB Ratio is 3.21 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Active Biotech AB focuses on the research and development of pharmaceuticals products within medical areas including neurodegenerative diseases, autoimmune/inflammatory disease and various forms of cancer. Its project portfolio contains both small molecules that are orally active immunomodulatory agents and antibody based immunotherapy. Its project portfolio includes both small orally active immunomodulatory molecules and antibody-based immunotherapy. Its pipeline products are: Tasquinimod, Laquinimod, and Naptumomab.
28GF Score
Get the complete analysis for OSTO:ACTI
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ACTI has been successfully added to your 
